SAMSUNG TESTS GALAXY WATCH 8 TO COMBAT GLP-1 MUSCLE LOSS

GLP-1 receptor agonists have gained widespread use for diabetes management and weight loss, but users frequently experience muscle loss alongside fat reduction. Samsung's partnership with MGH represents an effort to use wearable technology to monitor and mitigate this effect. The Galaxy Watch 8 would track metrics relevant to muscle health, potentially including activity levels, exercise patterns, and other physiological data. By monitoring these indicators, the device could help users maintain muscle mass through targeted fitness interventions. The testing phase will evaluate the watch's ability to provide actionable insights to GLP-1 patients. If successful, the collaboration could establish a new use case for smartwatches in managing medication side effects and inform future device capabilities. Samsung has not announced a timeline for results or details on how extensively the Galaxy Watch 8 will be tested.